Oncorus Shares Owned By Institutions vs. Current Valuation
| ONCRDelisted Stock | USD 0.04 0.01 14.71% |
For Oncorus profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncorus to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncorus utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncorus's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncorus over time as well as its relative position and ranking within its peers.
Oncorus |
Oncorus Current Valuation vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncorus's current stock value. Our valuation model uses many indicators to compare Oncorus value to that of its competitors to determine the firm's financial worth. Oncorus is considered to be number one stock in shares owned by institutions category among its peers. It also is rated top company in current valuation category among its peers reporting about 464,948 of Current Valuation per Shares Owned By Institutions. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncorus by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Oncorus Current Valuation vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Oncorus |
| = | 55.29 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Oncorus |
| = | 25.71 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Oncorus Current Valuation vs Competition
Oncorus is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is now estimated at about 212.48 Million. Oncorus retains roughly 25.71 Million in current valuation claiming about 12% of stocks in Biotechnology industry.
Oncorus Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncorus, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncorus will eventually generate negative long term returns. The profitability progress is the general direction of Oncorus' change in net profit over the period of time. It can combine multiple indicators of Oncorus, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Oncorus operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Oncorus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncorus. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncorus position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncorus' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Oncorus without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
| All Next | Launch Module |
Use Investing Themes to Complement your Oncorus position
In addition to having Oncorus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Medical Equipment Thematic Idea Now
Medical Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Medical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Medical Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Oncorus Stock
If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |